

Date: 02/03/2021

Dear Healthcare Professional,

Re: Ferring Urology-Oncology portfolio distribution agreement with Cipla Australia Pty. Ltd

We are writing to inform you that Ferring Pharmaceuticals have finalised an agreement with Cipla Limited for Cipla to exclusively market, distribute and support the use of Ferring's existing Urology-oncology drug portfolio in Australia.

Under this partnership, Cipla will be responsible for the marketing, distribution and support of a number of key existing products including FIRMAGON (degarelix), MINIRIN (desmopressin), NOCDURNA (desmopressin) and TESTAVAN (testosterone). Ferring will continue to maintain marketing authorisation and remain the sponsor for the products.

Ferring Australia has a longstanding commitment to patients and clinicians within the Urology and Endocrinology therapy areas. Through our partnership with Cipla, we're able to maintain and build on our existing relationships; and expand our engagement and support through Cipla's extensive reach with primary care providers

What this means for healthcare professionals, pharmacies and patients

Cipla will continue to supply Ferring's Urology-Oncology products through existing wholesalers - for pharmacies, please continue to order via your existing wholesaler(s).

Cipla will provide information on access to patient materials in due course. Product Information (PI) and Consumer Medicine Information (CMI) documents will continue to be accessible from Ferring Australia's website (www.ferring.com.au/products.html).

For PBS Information, refer to the PBS Schedule (www.pbs.gov.au)

Medical enquiries for the Urology-Oncology products can be directed to Cipla by email at: au.medinfo@cipla.com or telephone at: 03 9696 4413. Adverse event reports can be submitted by email to: drugsafety@cipla.com.

All Commercial & general product information queries should be directed to Stephen Bowne (National Sales Manager, Cipla) at stephen.bowne@cipla.com

If you have any other questions of Ferring, please call 02 9497 2300 or email enquiries@fering.com.

Yours sincerely,



Stephen Bowne
National Sales Manager
ANZ Cipla



Hardus van Vuuren
Cluster Head & General Manager -
Ferring

PBS Information: MINIRIN Melt and Tablets
Authority Required (STREAMLINED) for the
treatment of Primary Nocturnal Enuresis. Refer to
PBS Schedule for full authority information.

MINIRIN Nasal Spray and Nasal Drops. Authority Required
(STREAMLINED) for the treatment of
Cranial Diabetes Insidipus

PBS Information: TESTAVAN Authority required.
Refer to PBS Schedule for full authority information.

PBS Information: FIRMAGON Restricted benefit.
Locally advanced (equivalent to stage C) or
metastatic (equivalent to stage D) carcinoma of the prostate.

PBS Information: NOCDURNA Wafers
This product is not listed on the PBS.